CVRx ROCE

Mitä CVRx tekee? CVRx Inc is a medical technology company that is revolutionizing the global market for treatment-resistant hypertension patients with its innovative "Baroreflex Activation Therapy" (BAT) system. The company was founded in 2001 and has its headquarters, development, manufacturing, and distribution facility in Minneapolis, Minnesota. With its innovative products and medical expertise, the company aims to become a global leader in medical research and development of apps and medical devices. The company was founded by Dr. Robert Kieval and his partner in medical research, Dr. Casey Cunningham. Together, they identified a potential treatment gap for patients who were unresponsive to existing methods or unable to receive appropriate therapy due to comorbidities. They decided to develop a novel technology that activates the body's natural regulatory system, the baroreflex system. With a clinical expert team in Minneapolis, they developed an implantable device connected to specific pressure zones in the neck through an electrode. The device artificially stimulates the baroreflex and regulates the blood pressure system. After many years of clinical tests and studies, the company received FDA approval in 2019. The company is now publicly listed, and its products are available worldwide. CVRx's business model is based on the research, development, production, and marketing of innovative medical devices and technologies. The focus is on improving patients' quality of life and advancing medical research. The products and therapies are distributed globally through contractual partners and subsidiaries. In addition to developing and marketing medical devices, the company conducts research to develop innovative diagnostic and therapeutic methods. The needs of patients and medical research are always the central focus. CVRx Inc specializes in the development and manufacture of implantable electronic devices for the treatment of patients with chronic cardiovascular diseases. The company's main product is the BAROSTIM NEO System, which is CE-certified in Europe. The system consists of two components: an implanted device and an external remote control. The device is surgically placed below the collarbone, and an electrode is inserted into a carotid artery. The remote control is used to regulate the electrical impulses delivered by the device to the carotid artery, activating the baroreflex system. Clinical studies have shown that BAT therapy is effective in lowering systolic blood pressure in patients with severe and persistent hypertension and can also have positive effects on heart failure patients. The company plans to use the BAROSTIM NEO System for other conditions, such as chronic kidney disease or sleep apnea. CVRx also invests in the development of mobile applications and software to support data analysis and patient monitoring. In summary, CVRx Inc is a medical technology company specialized in the development and manufacture of implantable electronic devices. The company is revolutionizing the global market for treatment-resistant hypertension patients with its Baroreflex Activation Therapy (BAT) system. The company focuses on improving patients' quality of life and advancing medical research. In addition to the BAROSTIM NEO System, the company conducts research to develop innovative diagnostic and therapeutic methods. CVRx on yksi Eurpooliin suosituimmista yhtiöistä.